SCHEMBL23326490

SCHEMBL23326490

CNc1nc(C)nc(Cl)c1/C=C/C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 4/20 0.37
GAA P10253 2/20 0.37
KDM4E B2RXH2 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
NPC1 O15118 1/20 0.34
PDK2 Q15119 1/20 0.33
P2RX3 P56373 3/20 0.32
HDAC3 O15379 1/20 0.31
TNKS O95271 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HCAR2 Q8TDS4 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC10 Q969S8 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
TNKS2 Q9H2K2 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29059996 0.85 KMT2A (0.37) L3MBTL1ALDH1A1KDM4ESMN1; SMN2PDK2
SCHEMBL30556387 0.85 KMT2A (0.37) L3MBTL1ALDH1A1KDM4ESMN1; SMN2PDK2
SCHEMBL29918598 0.81 CA12 (0.38) L3MBTL1ALDH1A1KDM4ENPC1HCAR2
SCHEMBL29154708 0.79 L3MBTL1 (0.45) L3MBTL1ALDH1A1GAAKDM4ESMN1; SMN2
SCHEMBL27186830 0.79 L3MBTL1 (0.45) L3MBTL1ALDH1A1GAAKDM4ESMN1; SMN2
SCHEMBL23345270 0.76 ATM (0.44) SMN1; SMN2HCAR2
SCHEMBL29910329 0.76 ATM (0.44) SMN1; SMN2HCAR2
SCHEMBL23326581 0.76 CA1 (0.34) KDM4EPDK2LMNA
SCHEMBL25399541 0.75 L3MBTL1 (0.39) L3MBTL1ALDH1A1GAAKDM4ESMN1; SMN2
SCHEMBL24671926 0.74 LRRK2 (0.31) PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4620531-A2 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2025-09-24 EP disclosed
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2025-03-25 US disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 US disclosed
CN-116425742-A Bicyclic heteroaryl compounds and uses thereof 锐新医药公司 2023-07-14 CN disclosed
EP-4055017-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-09-14 EP disclosed
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof SOS1, SOST, SOS2 L3MBTL1 3075/4885ALDH1A1 3199/4885GAA 1568/4885
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 L3MBTL1 2150/4885ALDH1A1 3594/4885GAA 990/4885
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 L3MBTL1 2150/4885ALDH1A1 3594/4885GAA 990/4885
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof SOST, SOS1, SOS2 L3MBTL1 2150/4885ALDH1A1 3594/4885GAA 990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.